KR102776457B1 - 항-cd47 작용제-기초된 난소암 요법 - Google Patents

항-cd47 작용제-기초된 난소암 요법 Download PDF

Info

Publication number
KR102776457B1
KR102776457B1 KR1020207014145A KR20207014145A KR102776457B1 KR 102776457 B1 KR102776457 B1 KR 102776457B1 KR 1020207014145 A KR1020207014145 A KR 1020207014145A KR 20207014145 A KR20207014145 A KR 20207014145A KR 102776457 B1 KR102776457 B1 KR 102776457B1
Authority
KR
South Korea
Prior art keywords
antibody
pharmaceutical composition
dose
hu5f9
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207014145A
Other languages
English (en)
Korean (ko)
Other versions
KR20200068730A (ko
Inventor
크리스 히데미 미즈후네 타키모토
마크 핑 차오
옌스-피터 볼크메어
Original Assignee
포티 세븐, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포티 세븐, 엘엘씨 filed Critical 포티 세븐, 엘엘씨
Publication of KR20200068730A publication Critical patent/KR20200068730A/ko
Application granted granted Critical
Publication of KR102776457B1 publication Critical patent/KR102776457B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207014145A 2017-10-18 2018-10-18 항-cd47 작용제-기초된 난소암 요법 Active KR102776457B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762573835P 2017-10-18 2017-10-18
US62/573,835 2017-10-18
PCT/US2018/056441 WO2019079548A1 (en) 2017-10-18 2018-10-18 OVARIAN CANCER THERAPY BASED ON ANTI-CD47 AGENT

Publications (2)

Publication Number Publication Date
KR20200068730A KR20200068730A (ko) 2020-06-15
KR102776457B1 true KR102776457B1 (ko) 2025-03-06

Family

ID=64267915

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207014145A Active KR102776457B1 (ko) 2017-10-18 2018-10-18 항-cd47 작용제-기초된 난소암 요법

Country Status (12)

Country Link
US (2) US11802153B2 (enExample)
EP (2) EP4177270B1 (enExample)
JP (2) JP7308191B2 (enExample)
KR (1) KR102776457B1 (enExample)
CN (2) CN117771364A (enExample)
AU (1) AU2018351006B2 (enExample)
CA (1) CA3078253A1 (enExample)
ES (2) ES2989007T3 (enExample)
PL (2) PL3697817T3 (enExample)
PT (2) PT4177270T (enExample)
SI (2) SI3697817T1 (enExample)
WO (1) WO2019079548A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2796378T3 (es) 2016-01-11 2020-11-26 Forty Seven Inc Anticuerpos monoclonales anti-cd47 humanizados, de ratón o químicos
US11802153B2 (en) 2017-10-18 2023-10-31 Forty Seven, Inc. Anti-CD47 agent-based ovarian cancer therapy
EP4129336B1 (en) 2018-02-12 2025-05-07 Forty Seven, LLC Anti-cd47 agent-based treatment of cd20-positive cancer
CA3111323A1 (en) 2018-09-04 2020-03-12 Trillium Therapeutics Inc. Cd47 blockade with parp inhibition for disease treatment
AU2020410410A1 (en) 2019-12-17 2022-06-09 Pfizer Inc. Antibodies specific for CD47, PD-L1, and uses thereof
CN115361971A (zh) * 2020-04-06 2022-11-18 里兰斯坦福初级大学理事会 抗体制剂
JP2023530499A (ja) * 2020-06-22 2023-07-18 モルフォシス・アーゲー 抗ＣＤ１９抗体及びＳＩＲＰα－ＣＤ４７自然免疫チェックポイントを遮断するポリペプチドを含む抗腫瘍組み合わせ療法
WO2022171121A1 (zh) * 2021-02-10 2022-08-18 同润生物医药(上海)有限公司 治疗肿瘤的方法和组合
CA3193664A1 (en) * 2021-04-14 2022-10-20 Akeso Biopharma, Inc. Anti-cd47 monoclonal antibody and use thereof
KR20240019111A (ko) * 2021-06-10 2024-02-14 오노 야꾸힝 고교 가부시키가이샤 Cd47 저해 물질, 면역 체크포인트 저해 물질 및 표준 요법의 병용에 의한 암 치료법
CN115245516A (zh) * 2021-12-31 2022-10-28 郑州大学第一附属医院 一种抗卵巢癌肿瘤药物联用方法、体外和体内验证方法
US20250228938A1 (en) * 2022-03-08 2025-07-17 Whitehead Institute For Biomedical Research The combination of macrophage-directed immunotherapy and targeted agents for treatment of cancer
TWI876305B (zh) * 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100462A2 (en) 2015-12-11 2017-06-15 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with dual targeting of cd47 and egfr
WO2017121771A1 (en) * 2016-01-11 2017-07-20 Blink Biomedical Sas Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
WO2017127707A1 (en) * 2016-01-21 2017-07-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2735144T3 (es) 2008-01-15 2019-12-16 Univ Leland Stanford Junior Métodos para manipular fagocitosis mediada por CD47
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
US8758750B2 (en) 2009-09-15 2014-06-24 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-CD47 therapy for hematologic cancers
WO2011041453A1 (en) 2009-09-29 2011-04-07 The Board Of Trustees Of The Leland Stanford Junior University Isolation and use of melanoma cancer stem cells
JP6166177B2 (ja) 2010-05-14 2017-07-19 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体
WO2012088309A1 (en) 2010-12-21 2012-06-28 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor
SMT202000689T1 (it) 2012-01-17 2021-01-05 Univ Leland Stanford Junior Reagenti per sirp-alfa ad alta affinita'
BR112015013431A2 (pt) * 2012-12-12 2017-11-14 Vasculox Inc anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
ES2728066T3 (es) 2013-03-15 2019-10-22 Univ Leland Stanford Junior Métodos para la obtención de dosis terapéuticamente eficaces de agentes anti-CD47
JP6843611B2 (ja) 2013-04-29 2021-03-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 免疫を強化する抗ｃｄ４７因子の使用
US9945870B2 (en) 2013-05-17 2018-04-17 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
EP3116544A4 (en) 2014-03-11 2017-08-23 The Board of Trustees of the Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
WO2016023001A1 (en) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
ES2819451T3 (es) 2014-08-08 2021-04-16 Univ Leland Stanford Junior Agentes PD-1 de alta afinidad y procedimientos de uso
EP3209769B1 (en) 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
AU2016209268B2 (en) 2015-01-21 2021-04-29 The Board Of Trustees Of The Leland Stanford Junior University Macrophages eat cancer cells using their own calreticulin as a guide
US10358472B2 (en) 2015-05-06 2019-07-23 The Board Of Trustees Of The Leland Stanford Junior University High affinity CD47 analogs
US20180147257A1 (en) 2015-05-22 2018-05-31 The Board Of Trustees Of The Leland Stanford Junior University Btn3a ectodomain proteins and methods of use
WO2017019767A1 (en) 2015-07-27 2017-02-02 Myosotis, Llc Inhibition of CXCL12 in Cancer Immunotherapy
SI3341015T2 (sl) 2015-08-26 2024-03-29 The Board Of Trustees Of The Leland Stanford, Junior University Izboljšana deplecija ciljanih celic z blokado CD47 in imunostimulatornim agonistom
WO2017049251A2 (en) * 2015-09-18 2017-03-23 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
BR112018013094A2 (pt) 2015-12-28 2018-12-11 Merck Patent Gmbh combinação de inibidor de hdac e anticorpo de anti-pd-l1 para o tratamento de câncer ovariano
PL3442578T3 (pl) 2016-04-15 2022-06-20 The Board Of Trustees Of The Leland Stanford Junior University Sposoby określania i osiągania terapeutycznie skutecznych dawek środków anty-cd47 w leczeniu nowotworów
US10611842B2 (en) 2016-08-03 2020-04-07 The Board Of Trustees Of The Leland Stanford Junior University Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPα antibody therapy
WO2018031419A1 (en) 2016-08-12 2018-02-15 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for enhancing immunogenic cross-presentation of tumor antigens
WO2018081448A1 (en) 2016-10-26 2018-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
WO2018165015A1 (en) 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
US11802153B2 (en) 2017-10-18 2023-10-31 Forty Seven, Inc. Anti-CD47 agent-based ovarian cancer therapy
EP4194470A1 (en) 2017-10-18 2023-06-14 Forty Seven, Inc. Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
EP3807319A4 (en) 2018-06-13 2022-05-25 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for inducing phagocytosis
WO2020068431A1 (en) 2018-09-28 2020-04-02 The Board Of Trustees Of The Leland Stanford Junior University Analysis of polymorphisms in sirp-alpha for evaluating response to immunotherapy
WO2020160285A1 (en) 2019-02-01 2020-08-06 The Board Of Trustees Of The Leland Stanford Junior University SIRPα EXPRESSION ON T CELLS IS A BIOMARKER FOR FUNCTIONAL T CELLS DURING EXHAUSTION
WO2020163692A1 (en) 2019-02-08 2020-08-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100462A2 (en) 2015-12-11 2017-06-15 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with dual targeting of cd47 and egfr
WO2017121771A1 (en) * 2016-01-11 2017-07-20 Blink Biomedical Sas Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
WO2017127707A1 (en) * 2016-01-21 2017-07-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents

Also Published As

Publication number Publication date
US20200283520A1 (en) 2020-09-10
ES2932286T3 (es) 2023-01-17
CA3078253A1 (en) 2019-04-25
JP2023018062A (ja) 2023-02-07
CN117771364A (zh) 2024-03-29
KR20200068730A (ko) 2020-06-15
US11802153B2 (en) 2023-10-31
PT4177270T (pt) 2024-10-23
EP4177270B1 (en) 2024-07-31
JP7308191B2 (ja) 2023-07-13
CN111247172B (zh) 2023-11-14
PT3697817T (pt) 2023-01-02
SI3697817T1 (sl) 2023-01-31
PL3697817T3 (pl) 2023-01-23
AU2018351006A1 (en) 2020-05-07
EP3697817B1 (en) 2022-10-05
ES2989007T3 (es) 2024-11-25
EP3697817A1 (en) 2020-08-26
AU2018351006B2 (en) 2024-08-29
CN111247172A (zh) 2020-06-05
US20240150461A1 (en) 2024-05-09
PL4177270T3 (pl) 2024-11-18
JP2021500349A (ja) 2021-01-07
SI4177270T1 (sl) 2024-10-30
WO2019079548A1 (en) 2019-04-25
EP4177270A1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
KR102776457B1 (ko) 항-cd47 작용제-기초된 난소암 요법
US20240218077A1 (en) Anti-cd47 agent-based treatment of cd20-positive cancer
KR102763202B1 (ko) Cd47 및 egfr의 이중 표적화를 이용한 암의 치료
HK40092156B (en) Anti-cd47 agent-based ovarian cancer therapy
HK40092156A (en) Anti-cd47 agent-based ovarian cancer therapy
HK40036030A (en) Anti-cd47 agent-based ovarian cancer therapy
HK40036030B (en) Anti-cd47 agent-based ovarian cancer therapy
HK40086849A (en) Anti-cd47 agent-based treatment of cd20-positive cancer
HK40029255B (zh) 基於抗cd47剂的卵巢癌疗法
HK40029255A (en) Anti-cd47 agent-based ovarian cancer therapy
HK40084229A (en) Treatment of cancer with dual targeting of cd47 and egfr
HK40029258A (en) Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
HK40043124B (en) Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
HK40043124A (en) Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
HK1259512A1 (en) Treatment of cancer with dual targeting of cd47 and egfr

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1102 Extension of patent period due to registration delay

St.27 status event code: A-4-4-G10-G17-tad-PR1102

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 62